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OBJECTIVE—Malonyl coenzyme A (CoA) decarboxylase
(MCD) is a key enzyme responsible for malonyl-CoA turnover
and functions in the control of the balance between lipid and
glucose metabolism. We utilized RNA interference (siRNA)-
based gene silencing to determine the direct role of MCD on
metabolic responses in primary human skeletal muscle.
RESEARCH DESIGN AND METHODS—We used siRNA to
silence MCD gene expression in cultured human myotubes from
healthy volunteers (seven male and seven female) with no known
metabolic disorders. Thereafter, we determined lipid and glucose
metabolism and signal transduction under basal and insulin-
stimulated conditions.
RESULTS—RNA interference–based silencing of MCD expres-
sion (75% reduction) increased malonyl-CoA levels twofold and
shifted substrate utilization from lipid to glucose oxidation. RNA
interference–based depletion of MCD reduced basal palmitate
oxidation. In parallel with this reduction, palmitate uptake was
decreased under basal (40%) and insulin-stimulated (49%) condi-
tions compared with myotubes transfected with a scrambled
sequence. MCD silencing increased basal and insulin-mediated
glucose oxidation 1.4- and 2.6-fold, respectively, compared with
myotubes transfected with a scrambled sequence. In addition,
glucose transport and cell-surface GLUT4 content was increased.
In contrast, insulin action on IRS-1 tyrosine phosphorylation,
tyrosine-associated phosphatidylinositol (PI) 3-kinase activity,
Akt, and glycogen synthase kinase (GSK) phosphorylation was
unaltered between myotubes transfected with siRNA against
MCD versus a scrambled sequence.
CONCLUSIONS—These results provide evidence that MCD
silencing suppresses lipid uptake and enhances glucose uptake in
primary human myotubes. In conclusion, MCD expression plays
a key reciprocal role in the balance between lipid and glucose
metabolism. Diabetes 57:1508–1516, 2008
S
keletal muscle plays a vital role in whole-body
insulin-mediated glucose metabolism, with the
flux of intramyocellular fatty acids to lipogenesis
or oxidation impacting on glucose disposal. In
humans, intramyocellular lipid levels of skeletal muscle
are inversely correlated with whole-body insulin sensitiv-
ity (1). Increasing evidence suggests that extensive triacyl-
glycerol accumulation in skeletal muscle (i.e., ectopic fat
deposition) impairs insulin signaling and glucose uptake
and contributes to an intracellular energy imbalance char-
acteristic of type 2 diabetes and other metabolic diseases
(2–5). Dysregulation of the malonyl coenzyme A (CoA)
signaling mechanism has been proposed to contribute to
the development of lipid abnormalities in metabolic dis-
ease (6).
In lipogenic tissues such as liver and adipose tissue,
malonyl-CoA is the first intermediate regulator in the
synthesis of long-chain fatty acids (LCFAs). Malonyl-CoA
allosterically binds to carnitine palmitoyl transferase 1
(CPT-1), thereby inhibiting the enzyme and the transfer of
LCFA into the mitochondria (7). In nonlipogenic tissues,
such as cardiac and skeletal muscle, malonyl-CoA plays a
role in the control of intracellular energy balance by
inhibiting CPT-1 and reducing LCFA oxidation and/or
reesterification into triglycerides (8,9).
AMP-activated protein kinase (AMPK), an enzyme that
increases skeletal muscle fatty acid oxidation and insulin
sensitivity (10), is intimately linked to the malonyl-CoA
signaling mechanism (6). In mice lacking the AMPK sub-
strate acetyl-CoA carboxylase (ACC)2 and thus having
reduced malonyl-CoA levels, lipid oxidation is elevated
and lipid storage is reduced, suggesting that ACC and
malonyl-CoA play an important role in overall energy
balance (11).
AMPK modulates the concentration of malonyl-CoA by
concurrently phosphorylating and inhibiting ACC, the rate-
limiting enzyme in malonyl-CoA synthesis, and phosphor-
ylating and activating malonyl-CoA decarboxylase (MCD)
(6,12). Thus, malonyl-CoA is produced by ACC and catab-
olized by MCD. In skeletal muscle, changes in fuel avail-
ability and energy expenditure influence malonyl-CoA
concentration (13), presumably via reciprocal regulation
between AMPK and MCD (14). For example, malonyl-CoA
levels are increased in insulin-resistant tissues (15) and
reduced after exercise (16).
Whether MCD expression directly contributes to
changes in the uptake and oxidation of metabolic sub-
strates in skeletal muscle is unknown. Whole-body MCD
knockdown protects against the development of dietary-
induced insulin resistance (17), but the tissue-specific
mechanism(s) is unresolved since MCD plays a metabolic
role in multiple organs responsible for whole-body glucose
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and energy homeostasis (18,19). Recent studies performed
in mice demonstrated that MCD deletion in heart markedly
increases glucose oxidation and improves functional re-
covery after ischemia (20). Moreover, MCD overexpres-
sion in hypothalamus decreases LCFA and blunts the
hypothalamic responses to increased lipid availability,
thereby increasing food intake (21). Thus, MCD appears to
play a central role in regulating malonyl-CoA content and
fatty acid oxidation.
Here, we determined the direct role of MCD on glucose
and lipid metabolism in primary human skeletal muscle
myotubes by RNA interference–mediated (siRNA) gene
silencing. Molecular disruption of MCD altered substrate
utilization in skeletal muscle, as evidenced by decreased
lipid oxidation and increased glucose uptake and oxida-
tion. MCD appears to play a pivotal role in the metabolic
balance between glucose and lipid oxidation in skeletal
muscle.
RESEARCH DESIGN AND METHODS
Dulbecco’s modified Eagle’s medium (DMEM), Ham’s F-10 medium, fetal
bovine serum, penicillin, streptomycin, and fungizone were obtained from
GibcoBRL (Invitrogen, Stockholm, Sweden). Unless specified, the reagents
used in this study were obtained from Sigma. Radioactive reagents were
purchased from Amersham.
Skeletal muscle biopsies (rectus abdominus or vastus lateralis) were
obtained with the informed consent of the donors during scheduled abdomi-
nal surgery or through needle biopsy, respectively. Subjects (seven male and
seven female) had no known metabolic disorders. Mean age was 61  5 years
(BMI 26 kg/m2). The ethics committee at Karolinska Institutet approved the
study protocols. Satellite cells were isolated from muscle biopsies by trypsin
digestion and grown to confluent myoblasts that were differentiated into
myotubes as described (22,23).
siRNA transfection in myotubes. Myotubes were transfected using Lipo-
fectamine 2000 (Invitrogen). Differentiation media was changed to antibiotic-
free growth media on day 2 of myotube differentiation protocol. On day 3,
myotubes were transfected with individual siRNAs (1 g/ml) using Lipo-
fectamine 2000 in serum-free DMEM (incubation time 16 h). Pools of four
siRNA sequences directed against MCD or a scrambled sequence were used.
siRNA oligos for MCD were purchased from Dharmacon (Chicago, IL).
Myotubes were then washed with phosphate-buffered saline (PBS), and 2 ml
DMEM containing 2% fetal bovine serum was added to each well. On day 6 of
differentiation protocol, the cells were deprived of serum for 16 h before
further incubation in the absence or presence of insulin (120 nmol/l). Control
cultures were prepared without addition of MCD siRNA (control) or scram-
bled siRNA (24).
Analysis of mRNA expression. Myotubes prepared as described above were
washed three times with RNase-free PBS and then harvested directly for RNA
extraction (RNAeasy minikit; Qiagen). All RNA was DNase-treated before
reverse transcription (RQ1 RNase-free DNase; Promega). Total RNA concen-
tration was measured and reverse transcribed with oligo (dT) primers using
the SuperScript First Strand Synthesis System (Invitrogen). Reactions were
performed in duplicate in a 96-well format using a Prism 7000 Sequence
Detector and TaqMan-based technology (Applied Biosystems). Oligonucleo-
tide primers (sequences available on request) and TaqMan probes were
purchased from Applied Biosystems. Relative quantities of target transcripts
were calculated after normalization of the data using the standard curve
method.
Quantitation of malonyl-CoA, acetyl-CoA, CoASH, diacylglycerol
(DAG), and ceramide content. Myotubes prepared as described above were
lysed in 10% sulfosalicylic acid with 10 mmol/l dithiothreitol. The lysates were
spun at 15,000g and the supernate analyzed by liquid chromatography–mass
spectrometry without dilution or sample treatment. An Agilent 1100 series
capillary pump (Wilmington, DE) was interfaced with an LTQ ion trap mass
spectrometer (Thermo Fisher Scientific, San Jose, CA). The methodology used
was a modification of that reported by Minkler et al. (25). Analyte concentra-
tions were calculated by comparing the signal from triplicate injections to that
of a standard curve acquired both immediately before and after the sample
queue. DAG and ceramide content in human skeletal muscle cells was
determined by conversion to phosphorylation products by externally added
DAG kinase from Escherichia coli in the presence of [ -32P] ATP as described
(26).
Palmitate oxidation. Fatty acid oxidation was essentially determined as
previously described (27). Myoblasts were grown in a 25-cm2 cell culture flask
and differentiated to myotubes at 80% confluence. Before starting the
experiment, a 2-mm hole was made in the lid of each flask and two sheets of
24 mm Whatman filter (cat. no. 108340-24; VWR International) were encircled
with a gauze bandage compass. The filter compass was then pressed into the
inside of the culture flask lid. After 8 days differentiation, myotubes were
serum starved overnight and treated for 180 min with 0.4 Ci 1-[14C] palmitate
in 2 ml serum-free DMEM (containing 5 mmol/l glucose) with or without 120
nmol/l insulin at 37°C. After treatment, 200 l Solvable reagent (benzethonium
hydroxide; Packard) was added dropwise through the hole of the flask lid to
soak the filter. Thereafter, 300 l of 70% perchloric acid was injected through
the hole and filter. The lids were sealed with flexible film (Parafilm; Nordic EM
Supplies, Espoo, Finland). Flasks were then laid down with slight agitation for
1 h at room temperature. Thereafter, the filter compass was removed to a
scintillation tube with 10 ml scintillation liquid and 200 l ice-cold methanol
was added. The trapped [14CO2] in the filter was then counted in a liquid
scintillation counter. Protein content of each sample was determined by the
BioRad method.
Intracellular accumulation of radioactive palmitate (palmitate up-
take). As an indication of free fatty acid uptake, flasks from the palmitate
oxidation experiment described above were washed five times with Tris-
buffered saline plus Tween (TBST) and cells were lysed with 2 ml 0.03% SDS
for 2 h at room temperature with slight agitation. Lysates (400 l) were then
transferred to 4 ml scintillation fluid, and palmitate uptake, as determined by
the accumulated 1-[14C] in the lysate, was assessed by liquid scintillation
counting. The total lipid accumulation was calculated by adding the amount
oxidized to the amount accumulated.
Glucose oxidation. Cells were cultured in 25-cm2 flasks. Myotubes were
incubated for 60 min in 2 ml serum-free DMEM containing 5 mmol/l glucose
and 2 mCi/ml D-[U-14C] glucose in the absence or presence or insulin (120
nmol/l) at 37°C in 5% CO2-95% O2. Trapping of [
14CO2] to determine whether
the labeled glucose had been metabolized was performed as described above
for palmitate oxidation. Protein content of each sample was determined by the
BioRad method.
Glucose conversion into glycogen. Glycogen synthesis was determined by
assessing the conversion of labeled glucose into glycogen, as previously
described (24). Myotubes cultured in sixwell plates containing 5 mmol/l
glucose DMEM supplemented with D-[U-14C] glucose (1 Ci/ml; final specific
activity, 0.18 Ci/mol) were incubated in the absence or presence of insulin
(120 nmol/l) for 90 min at 37°C. Each experiment was performed on triplicate
wells.
Lactate concentration. Myotubes were stimulated with or without insulin
(120 nmol/l) in serum-free DMEM. Media (100 l) were collected in duplicates
and lactate concentration was determined as previously described (27), using
a lactate kit (A-108; Biochemical Research Service Center, University at
Buffalo, Buffalo, NY).
Glucose transport and cell surface GLUT1/4 content. Myotubes were
transfected with siRNA against a scrambled sequence or MCD as described
above. Control or transfected myotubes were incubated in the absence or
presence of insulin (120 nmol/l) for 1 h. 2-deoxyglucose uptake was per-
formed as previously described for primary human muscle cells (23,28).
Cell-surface GLUT1 and GLUT4 content was performed as previously
described for primary human muscle cells (28). Myotubes were incubated
as described for glucose transport, followed by incubation at 18°C for 5
min. Cells were then rinsed and incubated for 8 min with Krebs-Henseleit
bicarbonate buffer supplemented with 5 mmol/l HEPES and 0.1%
BSA, with 100 mol/l Bio-LC-ATB-BGPA {4,4-O-[2-[2-[2-[2-[2-[6-
(biotinylamino)hexanoyl]amino]ethoxy]ethoxy]ethoxy]-4-(1-azi-2,2,2,-
rifluoro-ethyl)benzoyl] amino-1,3-propanediyl bis-D-glucose} (a kind gift
from Dr. Geoffrey Holman, University of Bath, U.K.). Dishes were subse-
quently ultraviolet irradiated for 3 min. Cells were washed with PBS,
solubilized, and scraped into 1 ml PBS with 2% thesit (C12E9) and protease
inhibitors (10 g/ml aprotinin, 10 g/ml antipain, 10 g/ml leupetin, and
200 mol/l phenylmethylsulfonyl fluoride). Solubilized cell extracts were
then transferred to microtubes (Sarstedt, Nümbrecht, Germany) and
rotated for 60 min at 4°C. Cell lysates were centrifuged for 10 min at
20000g. The supernatant was collected, and protein concentration was
determined. Equal amount of protein was mixed with 50 l PBS-washed
streptavidin agarose beads (50% slurry; Pierce). The streptavidin-biotin
complex was incubated overnight at 4°C with end-to-end rotation. Beads
were washed three times with PBS-1% thesit, three times with PBS-0.1%
thesit, and twice with PBS. An aliquot (30 l) Laemmeli buffer was lamp
heated for 40 min. Photolabeled glucose transporters were eluted from the
beads by heating in 50 l Laemmeli buffer at 56°C for 20 min. Samples were
directly applied to SDS-PAGE and subjected to electrophoresis. Proteins
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were transferred and subjected to immunoblot analysis to determine
cell-surface GLUT1 and GLUT4 as described (28).
Insulin signaling. Myoblasts were incubated for 20 min in the absence or
presence of insulin (120 nmol/l) and then scraped into ice-cold homogenizing
buffer (20 mmol/l Tris pH 8.0, 135 mmol/l NaCl, 1 mmol/l MgCl2, 2.7 mmol/l
KCl, 10 mmol/l Na4P2O7, 0.5 mmol/l Na3VO4, 10 mmol/l NaF, 1 mol/l
microcystin, 1% Triton X-100, 10% vol/vol glycerol, 0.2 mmol/l phenylmethyl-
sulfonyl fluoride, 10 g/ml leupeptin, and 10 g/ml aprotinin). Cells were lysed
by repeated pipetting, and lysates were agitated for 60 min at 4°C and
subjected to centrifugation (12,000g for 10 min at 4°C). After protein deter-
mination, an aliquot of 300 g protein was immunoprecipitated overnight
(4°C) with anti-phosphotyrosine antibody coupled to protein A-sepharose
(Sigma). Phosphatidylinositol (PI) 3-kinase activity was assessed directly on
the protein A–sepharose beads as previously described (29). Reaction prod-
ucts were resolved by thin-layer chromatography and quantified using Phos-
phoImager Bio-Rad Laboratories (Richmond, CA).
Western blot analysis. Aliquots of cell lysate (20 g protein) or anti–IRS-1
immunodepleted samples were resuspended in Laemmli sample buffer. Pro-
teins were then separated by SDS-PAGE, transferred to polyvinylidene
difluoride membranes (Millipore, MA), blocked with 7.5% nonfat milk, washed
with TBST (10 mmol/l Tris HCl, 100 mmol/l NaCl, and 0.02% Tween 20), and
incubated with appropriate primary antibodies overnight at 4°C. Membranes
were washed with TBST and incubated with an appropriate secondary
antibody. Proteins were visualized by enhanced chemiluminescence and
quantified by densitometry. Phosphospecific antibodies against Akt (Ser473),
GSK/ (Ser 21/9), and AMPK (Thr172) were from Cell Signaling. The IRS-1
polyclonal antibody was from Upstate Biotechnology. The rabbit polyclonal
antibody to phosphotyrosine was from BD Transduction Laboratories.
Statistics. Results are presented as mean  SE. Differences between groups
were determined by two-way ANOVA or paired Student’s t test. When ANOVA
was applied, Fisher’s least-significant difference post hoc analysis was used to
identify significant differences.
RESULTS AND DISCUSSION
MCD silencing in human myotubes. The major pathway
for malonyl-CoA degradation is via MCD, which decar-
boxylates malonyl-CoA to acetyl-CoA. MCD inhibition has
been proposed as a novel strategy to treat ischemic heart
disease and obesity, namely by allowing full oxidation of
glucose rather than elevated lactic acid and proton pro-
duction leading to diminished cardiac efficiency (30). The
potential effects of MCD inhibition on peripheral tissues
such as skeletal muscle, a major tissue involved in the
regulation of whole body glucose homeostasis, are un-
known. Based on work in cardiac muscle, MCD inhibition
would be predicted to shift bioenergetics in skeletal
muscle from lipid to glucose oxidation. To test this hy-
pothesis, we used RNA interference to silence MCD gene
expression in differentiated myotubes. We have previously
utilized this approach to silence genes in the insulin-
signaling cascade in primary human skeletal muscle
(24,31). MCD gene expression was reduced 75% (P 
0.001) compared with that in cells that were either un-
transfected or transfected with scrambled siRNA (Fig. 1).
Cell survival was unaltered in MCD-depleted myotubes.
MCD depletion alters palmitate oxidation and up-
take. During and after a cardiac ischemic event, circulat-
ing free fatty acid levels are elevated and lipid oxidation
serves as a major source of oxidative metabolism. Genetic
or pharmacological inhibition of MCD in cardiac muscle
increases malonyl-CoA, thereby inhibiting lipid oxidation
and increasing glucose oxidation (30). MCD silencing
increased malonyl-CoA levels twofold (Fig. 2A), whereas
CoASH, acetyl-CoA, DAG, and ceramide levels were unal-
tered (Fig. 2B–E). An increase in malonyl-CoA inhibits
CPT-1, the rate-limiting enzyme in fatty acid import into
mitochondria for oxidation (7). Malonyl-CoA can bind to
CPT-1 via its regulatory domain and therefore inactivate
the enzyme (32); thus, we determined whether MCD gene
silencing alters lipid metabolism in human muscle. In
control cells and cells transfected with scrambled siRNA,
insulin suppressed palmitate oxidation 2.8-fold (Fig. 3A)
and increased the accumulation of intracellular palmitate
1.5-fold (Fig. 3B). RNA interference–mediated depletion of
MCD suppressed basal palmitate oxidation (Fig. 3A). This
response was similar to the effect of insulin to suppress
palmitate oxidation in control cells. Suppression of MCD
further reduced palmitate oxidation under insulin-stimu-
lated conditions. MCD silencing also decreased (40%) the
basal rate of palmitate uptake and markedly impaired
(49%) the insulin-stimulated response (Fig. 3B). We also
assessed the effects of MCD depletion on mRNA expres-
sion of fatty acid transport protein member (FATP)-1 and
pyruvate dehydrogenase kinase (PDK)4 (Table 1). FATP-1
facilitates the transport of fatty acids across the cell
membrane, and PDK4 phosphorylates and inactivates the
pyruvate dehydrogenase complex, which controls the en-
try of carbohydrates into the tricarboxylic cycle. MCD
silencing increased mRNA expression of FATP-1 and was
without effect on expression of PDK4. We were unable to
confirm these results at the level of protein expression as
a result of insufficient availability of sample. Collectively,
these results provide evidence that MCD plays a key role
in regulating lipid oxidation. Our results are compatible
with pharmacological studies that report chemical inhibi-
tion of MCD decreases lipid oxidation in mouse heart due
to an increase in the malonyl-CoA level (33). These results
are recapitulated in MCD	/	 mice (17), as evident by re-
duced rates of fat catabolism and protection from dietary-
induced insulin resistance despite elevated levels of skel-
etal muscle long-chain acyl-CoAs and a tendency for
increased triacylglycerol levels.
MCD depletion increases glucose metabolism. A re-
ciprocal relationship between lipid and glucose oxidation
has long been appreciated (34). Indeed chronic inhibition
of MCD using whole-body knockout mice (20) provides
protection against the development of glucose intolerance
and hyperglycemia associated with high-fat diet (17).
Interestingly, the respiratory exchange ratio was higher in
MCD	/	 mice fed a high-fat diet compared with that in
wild-type littermates, reflecting increased rates of glucose
rather than lipid oxidation at the whole-body levels. These
findings suggest that skeletal muscle glucose uptake and
catabolic metabolism may be enhanced as a consequence




























FIG. 1. Effect of MCD siRNA on mRNA expression. mRNA expression of
MCD in human skeletal muscle myotubes. Myotubes were transfected
with siRNA against MCD (siMCD) or a scrambled sequence. Untrans-
fected myotubes were used as control. MCD mRNA is reported relative
to 2-microglobulin mRNA expression. Results are expressed as
means  SE. *P < 0.05 vs. scrambled siRNA.
MCD REGULATES METABOLIC RESPONSES IN MUSCLE
1510 DIABETES, VOL. 57, JUNE 2008
whether MCD led to a reciprocal relationship between
lipid and glucose oxidation in primary human muscle cells.
Four days after transfection, glucose oxidation was as-
sessed under basal and insulin-stimulated conditions. In
control or myotubes transfected with scrambled siRNA,
insulin increased glucose oxidation 1.7-fold (Fig. 4A).
Gene silencing of MCD increased basal and insulin-
mediated glucose oxidation 1.4- and 2.6-fold, respectively.
The consequences of MCD silencing on glycogen syn-
thesis was next determined. In control or cells transfected
with scrambled siRNA, insulin increased glycogen synthe-
sis 1.8-fold (Fig. 4B). In myotubes in which MCD was
depleted, basal glycogen synthesis was increased by 1.3-
fold compared with that in untransfected cells. Insulin-
stimulated glucose incorporation to glycogen was
unaltered by MCD depletion. Glucose can be degraded
through anaerobic metabolism to produce lactate. The
increase in glucose metabolism can promote lactate pro-
duction by the conversion of pyruvate by lactate dehydro-
genase. Skeletal muscle is considered the major site of
lactate production (35). In control cells, insulin increased
lactate production 1.6-fold (Fig. 4C). siRNA-mediated
MCD silencing decreased basal and insulin-stimulated
lactate production. An increase in fasting plasma lactate
levels has been proposed as an independent risk factor for
development of type 2 diabetes (36,37). MCD inhibition
decreased the rate of glycolysis, as estimated by a reduc-
tion in lactate release, and augmented the rate of glycogen
synthesis. Alternatively, the reduced lactate production in
MCD-depleted myotubes may occur in response to the
increase in glucose oxidation rather than a decrease in
glycolysis.
MCD depletion increases glucose uptake but not
insulin signaling. To provide insight into the mechanism
by which suppression of MCD expression and fatty acid
oxidation lead to enhanced glucose oxidation, glucose
transport and cell surface glucose transporters were de-
termined. Four days after transfection, basal and insulin-
stimulated glucose uptake was assessed (Fig. 5A). Insulin
increased glucose uptake 1.7-fold in controls and in cells
transfected with scrambled siRNA. RNA interference–
mediated depletion of MCD increased basal glucose trans-
port compared with that in control myotubes. Insulin-
stimulated glucose transport was also increased in MCD-
depleted myotubes; however, this effect appeared to be a
consequence of the increased basal glucose uptake, since
the fold–insulin stimulation was similar to the effect noted
in control cells. Glucose transport across the cell mem-
brane is mediated by a family of structurally related
transport proteins that can be translocated from intracel-
lular sites to the plasma membrane. Cell-surface GLUT1
content was unaltered between basal and insulin-stimu-
lated conditions (Fig. 5B), consistent with the notion that
GLUT1 primarily mediates basal glucose transport (38).
Moreover, depletion of MCD did not alter cell-surface
GLUT1 levels. Insulin stimulation of glucose transport
activity correlates closely with the appearance of GLUT4
on the cell surface (38). Here, we report that insulin
increased cell-surface GLUT4 levels in primary human
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FIG. 2. Effect of MCD siRNA on intracellular lipid metabolites. Intracellular levels of malonyl-CoA (A), CoASH (B), acetyl-CoA (C),
diacylglycerol (DAG) (D), and ceramide (E) were determined in cultured human skeletal muscle myotubes transfected with siRNA against MCD
(siMCD) or a scrambled sequence (Scr). Results are expressed as means  SE/percentages of control. *P < 0.05 vs. scrambled siRNA.
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cell-surface GLUT4 content under basal and insulin-stim-
ulated conditions, and this response was comparable with
the observed changes in glucose transport and oxidation.
Thus, MCD inhibition promotes glucose transport by in-
creasing cell-surface GLUT4 levels and glucose metabo-
lism primarily via oxidative rather than nonoxidative
pathways.
Insulin regulates glucose and lipid metabolism by signal
transduction pathways involving protein phosphorylation
cascades (39). To determine whether the changes in lipid
and glucose metabolism that we observed were associated
with alterations in insulin signaling, we determined the
effect of MCD inhibition on insulin signaling (Fig. 6).
Insulin receptor tyrosine phosphorylation was increased
1.8-fold by insulin (Fig. 6A), and this response was unal-
tered by depletion of MCD. Similarly, IRS-1–associated PI
3-kinase activity (Fig. 6B) and Akt Ser473 phosphorylation
(Fig. 6C) were markedly increased in response to insulin
but not MCD knockdown. The increase in glucose trans-
port and metabolism observed in MCD-depleted cells in
the absence of changes in insulin signaling may be ex-
plained by the spare receptor and signaling capacity
leading to additional GLUT4 translocation. Indeed, the
concentration of insulin required to maximally activate
glucose transport corresponds to 15% of maximal recep-
tor kinase activity (40) and, therefore, changes in glucose
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FIG. 3. Effect of MCD siRNA on palmitate oxidation and uptake.
Palmitate oxidation (A) and uptake (B) under basal or insulin-stimu-
lated conditions in primary human skeletal myotubes. Palmitate oxi-
dation and uptake are reported as nanomoles per milligrams protein
per hour. Results are expressed as means  SE. *P < 0.05 vs.






































































FIG. 4. Effect of MCD siRNA on glucose metabolism. Glucose metabo-
lism and lactate release were determined in primary human skeletal
myotubes under basal or insulin-stimulated conditions. Glucose oxida-
tion (A), glycogen synthesis (B), and lactate production (C) are
reported as nanomoles per milligrams protein per hour. Results are
expressed as means  SE. *P < 0.05 vs. untransfected cells at basal;
#P < 0.05 vs. untransfected cells after insulin stimulation.
TABLE 1
mRNA content of select genes in human myotubes determined
using RT-PCR
Gene Scrambled siMCD
FATP-1 0.98  0.25 1.22  0.29*
PDK-4 0.99  0.16 0.89  0.24
AMPK-1 1.02  0.10 1.00  0.09
AMPK-2 0.96  0.24 0.74  0.13
ACC- 0.98  0.24 0.87  0.18
ACC- 0.98  0.32 1.12  0.27
Data are means  SE. Cells were transfected with siRNA against a
scrambled sequence or MCD (siMCD). Results are reported as
percentage of control (nontransfected myotubes) and normalized to
glyceraldehyde-3-phosphate dehydrogenase. Paired Student’s t test
comparisons were made between groups (scrambled vs. siMCD).
*Significantly different from scrambled (P  0.05).
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uptake can occur in the absence of an augmentation in
insulin signaling. Nevertheless, we cannot exclude the
possibility that MCD depletion leads to enhanced insulin
sensitivity in steps beyond Akt. To address this possibility,
we also tested whether MCD depletion altered phosphor-
ylation of GSK3. Akt inactivates GSK3, leading to the
dephosphorylation and activation of glycogen synthase
and, hence, to an acceleration of glycogen synthesis (41).
In skeletal muscle, insulin stimulates dephosphorylation
of glycogen synthase by inactivating GSK3 and GSK3
via phosphorylation of serine residues (42). Insulin in-
creased GSK3 and GSK3 serine phosphorylation two-
fold (Fig. 7), and this response was unaltered by MCD
depletion. Collectively, our data provide evidence that
MCD leads to changes in lipid and glucose oxidation,


























































































FIG. 5. Effect of MCD siRNA on glucose transport and cell-surface
glucose transporters. Glucose uptake and cell-surface GLUT1 and
GLUT4 were determined in primary human skeletal myotubes under
basal or insulin-stimulated conditions. Glucose uptake (A) is reported
as cpm per milligrams protein per min. Cell-surface GLUT1 (B) and
GLUT4 (C) are reported as arbitrary units. Representative immuno-
blots for cell-surface GLUT1 and GLUT4 are shown about each respec-
tive graph. Results are expressed as means  SE. *P < 0.05 vs.
untransfected cells at basal; #P < 0.05 vs. untransfected cells after
insulin stimulation.
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FIG. 6. Effect of MCD siRNA on insulin signaling. IRS-1 tyrosine
phosphorylation (A), tyrosine-associated PI 3-kinase activity (B), and
Akt Ser473 phosphorylation (C) were determined under basal or insu-
lin-stimulated conditions in primary human skeletal myotubes studied
under control conditions or after transfection with siRNA against a
scrambled sequence or MCD (siMCD). Representative immunoblots
are shown for IRS-1 tyrosine and Akt phosphorylation, respectively.
Representative phospho-image is shown for PI-3 kinase activity. Re-
sults are expressed as means  SE arbitrary units. *P < 0.05 vs.
untransfected cells at basal.
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MCD depletion does not affect AMPK phosphoryla-
tion. MCD regulates malonyl-CoA levels by signal trans-
duction via AMPK through phosphorylation and inhibition
of ACC, the rate-limiting enzyme in malonyl-CoA synthesis
(6,12). Under physiological conditions, fuel availability
and energy expenditure may influence malonyl-CoA levels
(13) by reciprocal regulation between AMPK and MCD
(14). Since we perturbed the malonyl-CoA pathway down-
stream of AMPK, we could not exclude the possibility that
an alteration in MCD expression may feedback on AMPK
activity. To address this issue, we assessed AMPK phos-
phorylation (Fig. 8). Myotubes were incubated in the
absence or presence of insulin, and AMPK Thr172 was
determined. AMPK phosphorylation was similar between
myotubes incubated under control conditions in the ab-
sence or presence of insulin. In myotubes transfected with
siRNA against a scrambled sequence, AMPK phosphoryla-
tion under insulin-stimulated conditions was reduced. This
finding was inconsistent with all other parameters studied.
Treatment of myotubes with siRNA against MCD was
without effect on AMPK phosphorylation. Thus, depletion
of MCD modifies malonyl-CoA levels downstream or inde-
pendently of AMPK. In addition, mRNA of AMPK-1 and
-2 subunits and ACC and ACC were unaltered between
myotubes transfected with siRNA against a scrambled
sequence or MCD versus control cells (Table 1).
Malonyl-CoA has been identified as a critical mediator in
the hypothalamic sensing of energy balance (11,18). Inhi-
bition of fatty acid synthase directly in the hypothalamus
increases the level of malonyl-CoA and suppresses food
intake, increases skeletal muscle fatty acid oxidation, and
causes weight loss (11). Conversely, hypothalamic overex-
pression of MCD (21), inhibition of ACC (11), or activation
of AMPK (43) to decrease the level of malonyl-CoA stim-
ulates food intake. While the long-term effect of skeletal
muscle MCD inhibition is unknown, chronic elevations in
the local concentration of malonyl-CoA due to glucose
infusion (44) or diabetes (13) are associated with periph-
eral and hepatic insulin resistance, due in part to an
increase in diacylglycerol content and feedback inhibition
on insulin-signaling cascades (45). Conversely, whole-
body deletion of MCD is associated with a shift from
incomplete -oxidation of lipids to glucose oxidation and
in high-fat fed mice, particularly during the dark/active
cycle when systemic substrate use is predominantly influ-
enced by the catabolic activity of skeletal muscle (17). The
direct effects of whole-body MCD inhibition on whole-
body glucose homeostasis in humans are difficult to pre-
dict, particularly in light of the potent hypothalamic effects
of malonyl-CoA to inhibit food intake.
In conclusion, we provide evidence that siRNA-
mediated gene silencing directly validates MCD as a key
modulator of skeletal muscle bioenergetics through coor-
dinated changes in substrate utilization (Fig. 9). Inhibition
of MCD in skeletal muscle shifts oxidation metabolic
substrates from lipids to glucose.
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FIG. 7. Effect of MCD siRNA on GSK3 phosphorylation. Serine phos-
phorylation of GSK3 and GSK3 was determined under basal or
insulin-stimulated conditions in primary human skeletal myotubes
studied under control conditions or after transfection with siRNA
against a scrambled sequence or MCD (siMCD). Representative immu-
noblots are shown. Results are expressed as means  SE. *P < 0.05 vs.





























FIG. 8. Effect of MCD siRNA on AMPK phosphorylation. AMPK Thr172
phosphorylation was determined under basal or insulin-stimulated
conditions in primary human skeletal myotubes studied under control
conditions or after transfection with siRNA against a scrambled se-
quence or MCD (siMCD). Representative immunoblots are shown.
Results are expressed as means  SE. *P < 0.05 vs. untransfected cells
at basal.
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FIG. 9. Signaling pathways involving ACC and MCD regulate lipid and glucose metabolism. Malonyl-CoA is produced by ACC and catabolized by
MCD. Malonyl-CoA is the first intermediate regulator in the synthesis of LCFA. Malonyl-CoA allosterically binds to CPT-1, thereby inhibiting the
enzyme and the transfer of long-chain fatty acids into the mitochondria. siRNA-mediated gene silencing of MCD in skeletal muscle shifts oxidation
and uptake of metabolic substrates from lipids to glucose.
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